吉非替尼治疗女性肺腺癌的临床观察

 【摘要】　目的　观察吉非替尼治疗化疗失败的晚期女性肺腺癌的疗效及副作用。方法　吉非替尼250 mg，口服，1次／d，连续服用至疾病进展或出现不可耐受的不良反应。患者分别在治疗后1个月及随后每2个月评价。结果　在可评价疗效的27例患者中，完全缓解（CR）1例（3.7 %），部分缓解（PR）11例（40.8 %），疾病稳定（SD）10例（37.0 %），疾病进展（PD）5例（18.5 %），总有效（CR+PR）率44.5 %，95 %可信区间为29 %～68 %；疾病控制率81.5 %，95 ％可信区间为62 %～94 %；症状缓解率为80.0 %；平均肿瘤进展时间（TTP）为7.2个月。不良反应主要为轻度的皮疹与腹泻。结论　吉非替尼治疗化疗失败的晚期女性肺腺癌疗效显著，副作用轻微。

Clinical observation of gefitinib in treatment of female patients with adenocarcinoma of lung

【Abstract】　Objective　To evaluate the efficacy and adverse effects of gifitinib in the treatment of fe－male patients with advanced adenocarcinoma of lung who had failed to previous chemotherapy. Methods　These patients received 250mg of gifitinib orally, once daily until disease progression or development of intol－erable toxic reaction. They were evaluated one month after treatment and every other month thereafter. Results　Among the 27 evaluable patients, there were 1 CR(3.7 %),11 PR(40.8 %), 10 SD(37.0 %), and 5 PD(18.5 %). The overall response rate was 44.5 %(95 % CI 29 %～68 %); and 22 patients (81.5 %) gained profit (CR+PR+SD) from the clinical therapy(95 % CI 62 %～94 %); the mean TTP was 7.2 months. Symptomatic improvement rate was 80.0 %. The main adverse effects were mild rash and diarrhea. Conclusion　gifitinib has significant efficacy in the treatment of female patients with advanced lung cancer who had failed to previous chemother－apy. Adverse effects are mild. gifitinib is a suitable therapy for these patients.